Richard John Hillman1, Tamzin Cuming, Teresa Darragh, Mayura Nathan, Michael Berry-Lawthorn, Stephen Goldstone, Carmella Law, Joel Palefsky, Luis F Barroso, Elizabeth A Stier, Céline Bouchard, Justine Almada, Naomi Jay. 1. 1Dysplasia and Anal Cancer Services, St Vincent's Hospital, Darlinghurst; 2Western Sydney Sexual Health Centre, Western Sydney Local Health District, Parramatta, New South Wales, Australia; 3Homerton University Hospital NHS Foundation Trust, Homerton, London, UK; 4Department of Pathology Mt. Zion Medical Center; 5Homerton Anal Neoplasia Service (HANS), London, UK; 6Anal Neoplasia Clinic, Research, and Education Center, San Francisco, CA; 7Laser Surgery Care, New York, NY; 8St Vincent's Centre for Applied Medical Research, St Vincent's Hospital, Darlinghurst, New South Wales, Australia; 9University of California-San Francisco, San Francisco, CA; 10Wake Forest Baptist Health Infectious Diseases/Internal Medicine, Winston-Salem, NC; 11Obstetrics and Gynecology, Dysplasia Services, Boston University Medical Center, Boston, MD; 12Centre Médical Berger Centre, Chemin Sainte-Foy, Québec, Canada; 13Anal Cancer Foundation, Dumbo, Brooklyn, NY; and 14UCSF ANCRE Center, Mount Zion Hospital, San Francisco, CA.
Abstract
OBJECTIVES: To define minimum standards for provision of services and clinical practice in the investigation of anal cancer precursors. METHODS: After initial face to face meetings of experts at the International Papillomavirus meeting in Lisbon, September 17 to 21, 2015, a first version was drafted and sent to key stakeholders. A complete draft was reviewed by the Board of the International Anal Neoplasia Society (IANS) and uploaded to the IANS Web site for all members to provide comments. The final draft was ratified by the IANS Board on June 22, 2016. RESULTS: The essential components of a satisfactory high-resolution anoscopy (HRA) were defined. Minimum standards of service provision, basic competencies for clinicians, and standardized descriptors were established. Quality assurance metrics proposed for practitioners included a minimum of 50 HRAs per year and identifying 20 cases or more of anal high-grade squamous intraepithelial lesions (HSILs). Technically unsatisfactory anal cytological samples at first attempt in high-risk populations should occur in less than 5% of cases. Where cytological HSIL has been found, histological HSIL should be identified in ≥ 90% of cases. Duration of HRA should be less than 15 minutes in greater than 90% of cases. Problematic pain or bleeding should be systematically collected and reported by 10% or lesser of patients. CONCLUSIONS: These guidelines propose initial minimum competencies for the clinical practice of HRA, against which professionals can judge themselves and providers can evaluate the effectiveness of training. Once standards have been agreed upon and validated, it may be possible to develop certification methods for individual practitioners and accreditation of sites.
OBJECTIVES: To define minimum standards for provision of services and clinical practice in the investigation of anal cancer precursors. METHODS: After initial face to face meetings of experts at the International Papillomavirus meeting in Lisbon, September 17 to 21, 2015, a first version was drafted and sent to key stakeholders. A complete draft was reviewed by the Board of the International Anal Neoplasia Society (IANS) and uploaded to the IANS Web site for all members to provide comments. The final draft was ratified by the IANS Board on June 22, 2016. RESULTS: The essential components of a satisfactory high-resolution anoscopy (HRA) were defined. Minimum standards of service provision, basic competencies for clinicians, and standardized descriptors were established. Quality assurance metrics proposed for practitioners included a minimum of 50 HRAs per year and identifying 20 cases or more of anal high-grade squamous intraepithelial lesions (HSILs). Technically unsatisfactory anal cytological samples at first attempt in high-risk populations should occur in less than 5% of cases. Where cytological HSIL has been found, histological HSIL should be identified in ≥ 90% of cases. Duration of HRA should be less than 15 minutes in greater than 90% of cases. Problematic pain or bleeding should be systematically collected and reported by 10% or lesser of patients. CONCLUSIONS: These guidelines propose initial minimum competencies for the clinical practice of HRA, against which professionals can judge themselves and providers can evaluate the effectiveness of training. Once standards have been agreed upon and validated, it may be possible to develop certification methods for individual practitioners and accreditation of sites.
Authors: Elizabeth A Stier; Shelly Y Lensing; Teresa M Darragh; Ashish A Deshmukh; Mark H Einstein; Joel M Palefsky; Naomi Jay; J Michael Berry-Lawhorn; Timothy Wilkin; Dorothy J Wiley; Luis F Barroso; Ross D Cranston; Rebecca Levine; Humberto M Guiot; Audrey L French; Deborah Citron; M Katayoon Rezaei; Stephen E Goldstone; Elizabeth Chiao Journal: Clin Infect Dis Date: 2020-04-10 Impact factor: 9.079
Authors: Vivian Colón-López; Meredith S Shiels; Mark Machin; Ana P Ortiz; Howard Strickler; Philip E Castle; Ruth M Pfeiffer; Eric A Engels Journal: J Clin Oncol Date: 2017-11-15 Impact factor: 44.544
Authors: Megan A Clarke; Li C Cheung; Thomas Lorey; Brad Hare; Rebecca Landy; Diane Tokugawa; Julia C Gage; Teresa M Darragh; Philip E Castle; Nicolas Wentzensen Journal: Clin Infect Dis Date: 2019-08-01 Impact factor: 9.079
Authors: Raúl U Hernández-Ramírez; Li Qin; Haiqun Lin; Wendy Leyden; Romain S Neugebauer; Keri N Althoff; Nancy A Hessol; Chad J Achenbach; John T Brooks; M John Gill; Surbhi Grover; Michael A Horberg; Jun Li; W Christopher Mathews; Angel M Mayor; Pragna Patel; Charles S Rabkin; Anita Rachlis; Amy C Justice; Richard D Moore; Eric A Engels; Michael J Silverberg; Robert Dubrow Journal: Clin Infect Dis Date: 2020-03-03 Impact factor: 9.079
Authors: Alan G Nyitray; Vanessa Schick; Michael D Swartz; Anna R Giuliano; Maria E Fernandez; Ashish A Deshmukh; Timothy J Ridolfi; Christopher Ajala; Bridgett Brzezinski; Micaela Sandoval; Belinda Nedjai; Jennifer S Smith; Elizabeth Y Chiao Journal: BMJ Open Date: 2021-06-29 Impact factor: 2.692